Diabetes treatment warning
Patients are being warned about the risk of diabetic ketoacidosis from the use of some diabetes treatments.
The TGA has issued a warning advising that “serious cases of diabetic ketoacidosis (DKA)” have been reported in patients taking prescription medicines that are inhibitors of sodium glucose co-transporter 2 (SGLT2).
“These medicines include canagliflozin, dapagliflozin or empagliflozin, which are used to help lower blood sugar levels in patients with type 2 diabetes,” the TGA advises.
Early signs and symptoms of DKA include abdominal pain, nausea, vomiting, anorexia, excessive thirst,